Adimmune Financial Statements From 2010 to 2024

4142 Stock  TWD 20.70  0.55  2.59%   
Adimmune Corp financial statements provide useful quarterly and yearly information to potential Adimmune Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Adimmune Corp financial statements helps investors assess Adimmune Corp's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Adimmune Corp's valuation are summarized below:
Adimmune Corp does not presently have any fundamental signals for analysis.
Check Adimmune Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adimmune Corp's main balance sheet or income statement drivers, such as , as well as many indicators such as . Adimmune financial statements analysis is a perfect complement when working with Adimmune Corp Valuation or Volatility modules.
  
This module can also supplement various Adimmune Corp Technical models . Check out the analysis of Adimmune Corp Correlation against competitors.

Adimmune Corp Company Current Valuation Analysis

Adimmune Corp's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Adimmune Corp Current Valuation

    
  15.44 B  
Most of Adimmune Corp's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adimmune Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Adimmune Corp has a Current Valuation of 15.44 B. This is 7.47% higher than that of the Biotechnology sector and 232.28% higher than that of the Health Care industry. The current valuation for all Taiwan stocks is 7.15% higher than that of the company.

Adimmune Corp Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Adimmune Corp's current stock value. Our valuation model uses many indicators to compare Adimmune Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adimmune Corp competition to find correlations between indicators driving Adimmune Corp's intrinsic value. More Info.
Adimmune Corp is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.21  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Adimmune Corp is roughly  4.71 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Adimmune Corp's earnings, one of the primary drivers of an investment's value.

About Adimmune Corp Financial Statements

Adimmune Corp investors use historical fundamental indicators, such as Adimmune Corp's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Adimmune Corp. Please read more on our technical analysis and fundamental analysis pages.
Adimmune Corporation manufactures and sells human vaccines in Taiwan. Adimmune Corporation was founded in 1965 and is based in Taichung City, Taiwan. ADIMMUNE CORPORATION operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange. It employs 384 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Adimmune Stock Analysis

When running Adimmune Corp's price analysis, check to measure Adimmune Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adimmune Corp is operating at the current time. Most of Adimmune Corp's value examination focuses on studying past and present price action to predict the probability of Adimmune Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adimmune Corp's price. Additionally, you may evaluate how the addition of Adimmune Corp to your portfolios can decrease your overall portfolio volatility.